Last updated on November 2017

EMR200147-501 Title A Phase 4, Observational, Multicenter, 10-year Prospective Cohort Safety Study Comparing Subjects with HIV-Associated Abdominal Lipohypertrophy Exposed to EGRIFTA® (Tesamorelin for injection) to a Similar Group of Subjects not Exposed to EGRIFTA®


Brief description of study

EMR200147-501 Title A Phase 4, Observational, Multicenter, 10-year Prospective Cohort Safety Study Comparing Subjects with HIV-Associated Abdominal Lipohypertrophy Exposed to EGRIFTA® (Tesamorelin for injection) to a Similar Group of Subjects not Exposed to EGRIFTA®

Detailed Study Description

The primary objective of the study is to evaluate the longterm effect of EGRIFTA®, 2 mg once daily subcutaneously (SC), on the development of malignancies in subjects with human immunodeficiency virus (HIV) infection and concomitant abdominal lipohypertrophy.

ClinicalTrials.gov Identifier: NCT01579695

Clinical Study Identifier: TX6021

Contact Investigators or Research Sites near you

Start Over

Crystal Nagle

Reading Hospital Clinical Trials Office
West Reading, PA USA

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.